These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8171728)

  • 1. Evaluation of commercially available antacid tablets.
    Nain CK; Singh K; Verma M; Vinayak VK; Ganguly NK
    Trop Gastroenterol; 1993; 14(4):139-43. PubMed ID: 8171728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neutralizing capacity and sodium content of antacid brands on the Kenyan market.
    Kibwage IO; Machine A; Hagos B; Hoogmartens J
    East Afr Med J; 1995 Mar; 72(3):194-7. PubMed ID: 7796775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antacid gel preparations available commercially in the Indian market.
    Nain CK; Singh K; Dhawan V; Vinayak VK; Ganguly NK
    Trop Gastroenterol; 1992; 13(2):70-4. PubMed ID: 1413102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the neutralising capacity of eight brands of antacids.
    Hagos B; Nganga JN; Juma FD; Ndegwa P
    East Afr Med J; 1989 Jun; 66(6):408-10. PubMed ID: 2791947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of liquid antacid products.
    Sherrill MC; Rudd GD
    Am J Hosp Pharm; 1982 Feb; 39(2):300-2. PubMed ID: 7058802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invitro evaluation of the neutralising capacity of twenty brands of antacids in Lagos, Nigeria.
    Adepoju-Bello AA; Akpabio UE; Ayoola GA; Coker HA; Enwuru NV
    Nig Q J Hosp Med; 2008; 18(3):153-5. PubMed ID: 19062480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro buffering capacities of proprietary non-particulate antacids available in New Zealand.
    Watts DW
    Anaesth Intensive Care; 1994 Apr; 22(2):184-6. PubMed ID: 8210023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do apparently healthy people use antacid tablets?
    Graham DY; Smith JL; Patterson DJ
    Am J Gastroenterol; 1983 May; 78(5):257-60. PubMed ID: 6846300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro comparison of the antacid potencies of almagate in tablets and suspension with those of other commercially available antacid preparations.
    Prieto R; Martinez-Tobed A; Fábregas JL; Beneyto JE
    Arzneimittelforschung; 1984; 34(10A):1360-4. PubMed ID: 6548920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing capacity and cost effectiveness of antacids.
    Drake D; Hollander D
    Ann Intern Med; 1981 Feb; 94(2):215-7. PubMed ID: 6781389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acid-neutralizing capacity of over-the-counter gastrointestinal medications].
    Iwazaki A; Tsuji A; Imai K; Nakanishi K
    Yakugaku Zasshi; 2014; 134(6):775-80. PubMed ID: 24882655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation of intelligent tablets with an antacid effect.
    Bajdik J; Korbely A; Pintye-Hódi K
    Pharm Dev Technol; 2009; 14(5):471-5. PubMed ID: 19552554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro determination of the neutralizing capacity of antacids].
    Brunner H
    Z Gastroenterol; 1983 Mar; 21 Suppl():22-5. PubMed ID: 6858407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antacids: A comparison of their in vitro neutralizing capacity in hydrochloric acid and in acidified peptone solution (author's transl)].
    Walther C; Herzog P; Hissnauer KH; Kühl HJ; Holtermüller KH
    Z Gastroenterol; 1982 May; 20(5):263-72. PubMed ID: 7102017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Users and utilization patterns of over-the-counter acid inhibitors and antacids in The Netherlands.
    Van Vliet EP; Kuipers EJ; Steyerberg EW; Siersema PD
    Scand J Gastroenterol; 2008; 43(6):662-8. PubMed ID: 18569982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I.
    al Gohary OM
    Boll Chim Farm; 1996 Dec; 135(11):621-37. PubMed ID: 9066172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of antacids "in vitro"].
    Alvarez de Saldaña S; de Ramírez AF; Ramírez Mata M
    Rev Gastroenterol Mex; 1978; 43(3):127-30. PubMed ID: 33434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chewable Antacid Tablets: Are Disintegration Tests Relevant?
    Nyamweya NN; Kimani SN; Abuga KO
    AAPS PharmSciTech; 2020 May; 21(5):139. PubMed ID: 32419049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial.
    Sulz MC; Manz M; Grob P; Meier R; Drewe J; Beglinger C
    Digestion; 2007; 75(2-3):69-73. PubMed ID: 17496418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid neutralization capacity of Canadian antacid formulations.
    MacCara ME; Nugent FJ; Garner JB
    Can Med Assoc J; 1985 Mar; 132(5):523-7. PubMed ID: 3971269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.